Stoke Therapeutics (STOK) Interest & Investment Income (2019 - 2026)
Stoke Therapeutics' (STOK) quarterly Interest & Investment Income came in at -$658000.0 in Q1 2026, down 122.77% year-on-year from $2.9 million in Q1 2025, and down 778.35% quarter-over-quarter from $97000.0 in Q4 2025.
Stoke Therapeutics (STOK) Interest & Investment Income (2019 - 2026) Analysis & Trends
Stoke Therapeutics' Interest & Investment Income history runs 8 years deep, the most recent figure standing at -$658000.0 for Q1 2026.
- On a quarterly basis, Interest & Investment Income fell 122.77% year-over-year to -$658000.0 in Q1 2026; TTM through Mar 2026 was -$11000.0, a 100.4% decrease from a year earlier, with the FY2025 full-year figure at $694000.0, up 646.46% from the prior year.
- Interest & Investment Income eased to -$658000.0 in Q1 2026 per STOK's latest filing, from $97000.0 in the prior quarter.
- Across five years, Interest & Investment Income topped out at $2.9 million in Q1 2025 and bottomed at -$658000.0 in Q1 2026.
- The 5-year median for Interest & Investment Income is $123000.0 (2023), against an average of $170352.9.
- Across the five-year window, Interest & Investment Income tumbled 2966.67% in 2022 and jumped 11941.67% in 2025, its largest moves.
- Year by year, Interest & Investment Income stood at $528000.0 in 2022, then slumped by 76.7% to $123000.0 in 2023, then tumbled by 357.72% to -$317000.0 in 2024, then jumped by 130.6% to $97000.0 in 2025, then plunged by 778.35% to -$658000.0 in 2026.
- Per Business Quant, the three latest STOK Interest & Investment Income figures stand at -$658000.0 (Q1 2026), $97000.0 (Q4 2025), and $350000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 27.66 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 114.80 Mn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -65.80 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 48.00 Mn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 19.51 Mn |
| 10 | Stoke Therapeutics | 1.86 Bn | 1.52 Bn | - | -658,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -658,000.00 |
| Dec 31, 2025 | 97,000.00 |
| Sep 30, 2025 | 350,000.00 |
| Jun 30, 2025 | 200,000.00 |
| Mar 31, 2025 | 2.89 Mn |
| Dec 31, 2024 | -317,000.00 |
| Sep 30, 2024 | 181,000.00 |
| Jun 30, 2024 | -15,000.00 |
| Mar 31, 2024 | 24,000.00 |
| Dec 31, 2023 | 123,000.00 |
| Sep 30, 2023 | 232,000.00 |
| Jun 30, 2023 | 219,000.00 |
| Mar 31, 2023 | 577,000.00 |
| Dec 31, 2022 | 528,000.00 |
| Sep 30, 2022 | -427,000.00 |
| Jun 30, 2022 | -592,000.00 |
| Mar 31, 2022 | -516,000.00 |
| Dec 31, 2021 | -146,000.00 |
| Sep 30, 2021 | 20,000.00 |
| Jun 30, 2021 | -42,000.00 |